The cutoff values indicating the induction of PD-1/PD-L1 antibodies and for predicting the efficacy of the PD-1/PD-L1 blockade in patients with thymic carcinoma are not necessarily the same as those in patients with lung cancer. This evidence concerns the gene CD274 and lung carcinoma.